Candriam SCA’s Aurinia Pharmaceuticals AUPH Stock Holding History

Candriam SCA’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-130,000	Closed	-$852K	–	748
2019 Q2	$852K	Sell	130,000 -27,500	-17%	-$175K	0.01%	681
2019 Q1	$1.02M	Hold	157,500	–	–	0.01%	622
2018 Q4	$1.07M	Hold	157,500	–	–	0.02%	581
2018 Q3	$1.05M	Hold	157,500	–	–	0.01%	615
2018 Q2	$887K	Buy	157,500 +39,500	+33%	+$220K	0.01%	633
2018 Q1	$612K	Hold	118,000	–	–	0.01%	648
2017 Q4	$535K	Hold	118,000	–	–	0.01%	666
2017 Q3	$740K	Hold	118,000	–	–	0.01%	613
2017 Q2	$723K	Hold	118,000	–	–	0.01%	622
2017 Q1	$866K	Buy	+118,000	New	+$545K	0.02%	586

Other funds holding AUPH

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA's AUPH Position: Q3 2019 in Review

Candriam SCA sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2019, closing a stake of 130,000 shares — an estimated $852K sold.

Candriam SCA first reported a position in AUPH in Q1 2017 and held it in 10 quarters. The position peaked at $1.07M in Q4 2018. 72 funds tracked by Wall St. Rank hold AUPH as of Q3 2019.

Candriam SCA reported no remaining Aurinia Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Candriam SCA sold 130,000 Aurinia Pharmaceuticals shares in Q3 2019, an estimated $852K.
Candriam SCA first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 10 quarters.
Candriam SCA's Aurinia Pharmaceuticals position peaked at $1.07M in Q4 2018.
72 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2019.

Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.